Review Article
Protracted inhibition of vascular endothelial growth factor signaling improves survival in metastatic colorectal cancer: A systematic review Francesco Montagnani, Greta Di Leonardo, Mariasimona Pino, Simona Perboni, Angela Ribecco, Luisa Fioretto Oncology Department, Istituto Tumori Toscano (I.T.T.), Azienda Sanitaria di Firenze, Piazza Santa Maria Nuova 1, Florence 50122, Italy
ABSTRACT Clinical data suggest that beyond-progression, the blockade of angiogenesis is associated with improved survivals in colorectal cancer. We conducted a systematic review to investigate the therapeutic effects of antiangiogenic drugs administered as later lines of treatment in patients already progressed to a previous anti-VEGF based treatment. An extensive literature search was conducted. Hazard ratios (HR) for progression (PFS) and death (OS) were extracted. An inverse-variance meta-analysis model was implemented. 6 randomized controlled trials were retrieved, including 3407 patients, treated with different antiangiogenic drugs. All of them had progressed during or after a previous line of treatment with bevacizumab. Overall, both PFS (HR=0.63, P
Protracted inhibition of vascular endothelial growth factor signaling improves survival in metastatic colorectal cancer: A systematic review Francesco Montagnani, Greta Di Leonardo, Mariasimona Pino, Simona Perboni, Angela Ribecco, Luisa Fioretto Oncology Department, Istituto Tumori Toscano (I.T.T.), Azienda Sanitaria di Firenze, Piazza Santa Maria Nuova 1, Florence 50122, Italy
ABSTRACT Clinical data suggest that beyond-progression, the blockade of angiogenesis is associated with improved survivals in colorectal cancer. We conducted a systematic review to investigate the therapeutic effects of antiangiogenic drugs administered as later lines of treatment in patients already progressed to a previous anti-VEGF based treatment. An extensive literature search was conducted. Hazard ratios (HR) for progression (PFS) and death (OS) were extracted. An inverse-variance meta-analysis model was implemented. 6 randomized controlled trials were retrieved, including 3407 patients, treated with different antiangiogenic drugs. All of them had progressed during or after a previous line of treatment with bevacizumab. Overall, both PFS (HR=0.63, P
